CAMBRIDGE, MA - Vedanta Biosciences, Inc., a biotechnology research company focused on developing therapies that modulate pathways of interaction between the human microbiome and the host immune system, has raised $106.5 million in its latest funding round. The financing was led by Korea Investment Partners and included Hambro Perks, Seventure Partners, Pfizer, Revelation Partners, K2 HealthVentures, PEAK6, QUAD Investment Management, PureTech Health, Korea Investment & Securities Co. Ltd, Reimagined Ventures, Skyviews Life Science, and AMR Action Fund.

The funds raised will be used to support the continued development of Vedanta's pipeline of microbiome-based therapies, which aim to address a wide range of autoimmune, metabolic, infectious, and other diseases.

"Our team is thrilled to have the support of such a diverse group of investors who share our vision for transforming human health through the microbiome," said Bernat Olle, co-founder of Vedanta Biosciences. "The microbiome is a complex and fascinating ecosystem that holds immense potential for new therapies. With this funding, we can accelerate our efforts to develop new treatments for patients in need."